The results of three studies could usher in a new era of fixed-dose oral thromboprophylaxis. Prophylactic anticoagulation is recommended practice following total knee and hip arthroplasty. Commonly ...

Oral edoxaban showed superior results to subcutaneous enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty, according to findings published in Thrombosis Journal. “In ...

Please provide your email address to receive an email when new articles are posted on . Extended prophylaxis with the oral anticoagulant dabigatran was superior in efficacy to subcutaneous enoxaparin ...

Low-molecular-weight heparins such as enoxaparin have shown benefit in MI and unstable angina and have been more effective in preventing venous thrombosis than unfractionated heparin. The latter is, ...

In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit MAGELLAN study meets primary efficacy endpoints of ...

ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superior to Enoxaparin in the Prevention of Venous Thromboembolism Following Knee Replacement Surgery Phase ...

(HealthDay News) – In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration ...

Oral rivaroxaban (Xarelto; Bayer/Janssen) is superior to subcutaneous enoxaparin in preventing venous thromboembolism (VTE) without increasing bleeding in patients undergoing nonmajor orthopedic ...

A phase III study has shown that for patients undergoing knee replacement surgery, oral rivaroxaban is better than subcutaneous enoxaparin at preventing blood clots (venous thromboembolism/VTE). The ...

HealthDay News— For hospitalized, acutely ill medical patients, use of enoxaparin plus elastic stockings with graduated compressions, does not reduce the rate of death from any cause at 30 days, ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...

Two new major studies suggest that anticoagulant therapy with enoxaparin is an effective alternative to heparin therapy for patients with acute coronary syndromes (ACS), according to articles in the ...